Q1 Earnings Estimate for ALLO Issued By William Blair

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Research analysts at William Blair issued their Q1 2026 EPS estimates for Allogene Therapeutics in a report released on Friday, March 14th. William Blair analyst S. Corwin expects that the company will earn ($0.29) per share for the quarter. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Several other equities research analysts also recently weighed in on ALLO. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a research note on Friday. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Friday. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.40.

Allogene Therapeutics Trading Up 2.6 %

Shares of ALLO opened at $1.94 on Monday. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.74. The company has a market cap of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02. The company’s fifty day simple moving average is $1.94 and its 200-day simple moving average is $2.31.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.

Institutional Trading of Allogene Therapeutics

A number of institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after buying an additional 5,642 shares in the last quarter. Invesco Ltd. boosted its stake in Allogene Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 127,486 shares of the company’s stock worth $272,000 after purchasing an additional 8,359 shares in the last quarter. ProShare Advisors LLC boosted its stake in Allogene Therapeutics by 25.6% in the 4th quarter. ProShare Advisors LLC now owns 46,082 shares of the company’s stock worth $98,000 after purchasing an additional 9,388 shares in the last quarter. Nordea Investment Management AB boosted its stake in Allogene Therapeutics by 2.1% in the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock worth $986,000 after purchasing an additional 9,635 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Allogene Therapeutics by 28.9% in the 4th quarter. Teacher Retirement System of Texas now owns 43,877 shares of the company’s stock worth $93,000 after purchasing an additional 9,839 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Allogene Therapeutics news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,710 shares of company stock worth $92,125 in the last three months. Corporate insiders own 24.30% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).